Terms: = Pancreatic cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS
53 results:
1. A multicenter, randomized phase 2 study to establish combinations of cbp501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T; Nguyen A; Misleh J; Cline VJ; Johns M; Shumway N; Paulson S; Siegel R; Larson T; Messersmith W; Richards D; Chaves J; Pierce E; Zalupski M; Sahai V; Orr D; Ruste SA; Haun A; Kawabe T
Eur J Cancer; 2024 Apr; 201():113950. PubMed ID: 38422585
[TBL] [Abstract] [Full Text] [Related]
2. Acetylation reprograms MITF target selectivity and residence time.
Louphrasitthiphol P; Loffreda A; Pogenberg V; Picaud S; Schepsky A; Friedrichsen H; Zeng Z; Lashgari A; Thomas B; Patton EE; Wilmanns M; Filippakopoulos P; Lambert JP; Steingrímsson E; Mazza D; Goding CR
Nat Commun; 2023 Sep; 14(1):6051. PubMed ID: 37770430
[TBL] [Abstract] [Full Text] [Related]
3. Modulation of cellular metabolism by protein crotonylation regulates pancreatic cancer progression.
Zheng Y; Zhu L; Qin ZY; Guo Y; Wang S; Xue M; Shen KY; Hu BY; Wang XF; Wang CQ; Qin LX; Dong QZ
Cell Rep; 2023 Jul; 42(7):112666. PubMed ID: 37347667
[TBL] [Abstract] [Full Text] [Related]
4. Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia.
Wang L; Gu S; Chen F; Yu Y; Cao J; Li X; Gao C; Chen Y; Yuan S; Liu X; Qin J; Zhao B; Xu P; Liang T; Tong H; Lin X; Feng XH
Signal Transduct Target Ther; 2023 Mar; 8(1):120. PubMed ID: 36959211
[TBL] [Abstract] [Full Text] [Related]
5. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway.
Wang Y; Qin C; Zhao B; Li Z; Li T; Yang X; Zhao Y; Wang W
J Transl Med; 2023 Mar; 21(1):201. PubMed ID: 36932397
[TBL] [Abstract] [Full Text] [Related]
6. Establishment and Molecular Characterization of Two Patient-Derived pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.
Braun R; Lapshyna O; Watzelt J; Drenckhan M; Künstner A; Färber B; Hael AAM; Bolm L; Honselmann KC; Konukiewitz B; Castven D; Spielmann M; Gorantla SP; Busch H; Marquardt JU; Keck T; Wellner UF; Ungefroren H
Cells; 2023 Feb; 12(4):. PubMed ID: 36831254
[TBL] [Abstract] [Full Text] [Related]
7. Blood-Based Diagnosis and Risk Stratification of Patients with pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN).
Zhang C; Al-Shaheri FN; Alhamdani MSS; Bauer AS; Hoheisel JD; Schenk M; Hinz U; Goedecke P; Al-Halabi K; Büchler MW; Giese NA; Hackert T; Roth S
Clin Cancer Res; 2023 Apr; 29(8):1535-1545. PubMed ID: 36516200
[TBL] [Abstract] [Full Text] [Related]
8. Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc.
Zhang M; Zhang L; Zhou M; Wang E; Meng B; Li Q; Wang X; Wang Y; Li Q
Int J Oncol; 2023 Jan; 62(1):. PubMed ID: 36416310
[TBL] [Abstract] [Full Text] [Related]
9. A Gastrectomy for early-stage gastric cancer patients with or without preserving celiac branches of vagus nerves: A meta-analysis.
Jin T; Chen ZH; Liang PP; Li ZD; He FJ; Chen ZW; Hu JK; Yang K
Surgery; 2023 Feb; 173(2):375-382. PubMed ID: 36379744
[TBL] [Abstract] [Full Text] [Related]
10. Safety, tolerability, and anti-fibrotic efficacy of the cbp/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Kimura K; Kanto T; Shimoda S; Harada K; Kimura M; Nishikawa K; Imamura J; Ogawa E; Saio M; Ikura Y; Okusaka T; Inoue K; Ishikawa T; Ieiri I; Kishimoto J; Todaka K; Kamisawa T
EBioMedicine; 2022 Jun; 80():104069. PubMed ID: 35605429
[TBL] [Abstract] [Full Text] [Related]
11. A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models.
Zhong Z; Harmston N; Wood KC; Madan B; Virshup DM
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35536676
[TBL] [Abstract] [Full Text] [Related]
12. Hepatoid carcinoma and related entities of the extrahepatic bile duct: A clinicopathological study of four cases.
Okura K; Esaki M; Nara S; Ban D; Takamoto T; Shimada K; Hiraoka N
Pathol Int; 2022 Jun; 72(6):332-342. PubMed ID: 35472251
[TBL] [Abstract] [Full Text] [Related]
13. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer.
Principe DR; Xiong R; Li Y; Pham TND; Kamath SD; Dubrovskyi O; Ratia K; Huang F; Zhao J; Shen Z; Thummuri D; Daohong Z; Underwood PW; Trevino J; Munshi HG; Thatcher GRJ; Rana A
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35064087
[TBL] [Abstract] [Full Text] [Related]
14. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.
van Riet J; van de Werken HJG; Cuppen E; Eskens FALM; Tesselaar M; van Veenendaal LM; Klümpen HJ; Dercksen MW; Valk GD; Lolkema MP; Sleijfer S; Mostert B
Nat Commun; 2021 Jul; 12(1):4612. PubMed ID: 34326338
[TBL] [Abstract] [Full Text] [Related]
15. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer.
Ono H; Kato T; Murase Y; Nakamura Y; Ishikawa Y; Watanabe S; Akahoshi K; Ogura T; Ogawa K; Ban D; Kudo A; Akiyama Y; Tanaka S; Ito H; Tanabe M
Sci Rep; 2021 May; 11(1):10078. PubMed ID: 33980911
[TBL] [Abstract] [Full Text] [Related]
16. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in cancer.
Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
[TBL] [Abstract] [Full Text] [Related]
17. Celiac Plexus Block Complications: A Case Report and Review of the Literature.
Gupta R; Madanat L; Jindal V; Gaikazian S
J Palliat Med; 2021 Sep; 24(9):1409-1412. PubMed ID: 33395560
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
[TBL] [Abstract] [Full Text] [Related]
19. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract] [Full Text] [Related]
20. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription.
Liu S; Zheng Y; Zhang Y; Zhang J; Xie F; Guo S; Gu J; Yang J; Zheng P; Lai J; Yin L; Wang H
Theranostics; 2020; 10(23):10634-10651. PubMed ID: 32929371
[No Abstract] [Full Text] [Related]
[Next]
